The advantages and long-term effects of extracurricular scientific research on undergraduate college students in lots of international locations have been intensively investigated, but it surely stays obscure for Chinese medical college students. In this examine, we investigated the end result of 60 medical college students who’ve participated in extracurricular scientific research at Jinan University Medical School over a interval of 7 years (2011-2018). The outcomes revealed that these college students have contributed to 31 biomedical science articles in respected educational journals, as first- or co-authors.
Furthermore, additionally they independently procured numerous funding based mostly on their research achievements, and smaller awards for achievements in conferences and competitions. Assessment of the grade level common rating of these college students revealed that conducting extracurricular scientific research didn’t have an effect on their routine medical examine and examination grades (P>0.05). The college students benefited from collaborating in extracurricular research, by buying the potential to assume scientifically and enhancing their communication abilities.
In addition, the medical college students had been motivated to enlist for postgraduate research in order that they might additional embark in scientific research. In sum, Chinese medical college students are succesful of collaborating in scientific research and make a big contribution to science. Linear regressions had been adjusted for gender, anticipated specialty alternative, parental schooling, dwelling standing, monetary insecurity, randomization group and baseline JSE-S.
This examine was performed between February and March 2019, in the Eastern area of Saudi Arabia, utilizing scientific pharmacy college students at the two universities that supply a pharmacy program there (King Faisal University and Imam Abdulrahman bin Faisal University). An digital questionnaire instrument was tailored to discover the intentions of and boundaries to hold out medical research amongst the college students.
Descriptive statistics are introduced as frequencies and percentages. A χ2 check was used to discover any statistically vital distinction between the pupil demographics and the intentions and boundaries relating to medical research. P ≤ 0.05 was thought-about statistically vital. Our examine highlights that the intention amongst scientific pharmacy college students to hold out medical research was poor. Educational establishments are suggested to offer extra monetary and logistic assist to their medical researchers.
Knowledge and attitudes of U.S. medical college students relating to the care of Asian American sufferers: a cross-sectional survey examine
Asian Americans (AsAm) are a quickly rising inhabitants in the U.S. With this rising inhabitants, U.S. healthcare suppliers have to be outfitted to offer culturally competent look after AsAm sufferers. This challenge surveyed U.S. medical college students on their information of and attitudes in the direction of AsAm to evaluate predictors of readiness to look after AsAm sufferers.
This cross-sectional examine surveyed medical college students who had accomplished at the least one scientific rotation. The survey was distributed on-line to 9 medical faculties all through the U.S. The survey measured self-rated information of, consolation with, cultural competency (CC) in the direction of, and specific biases in the direction of AsAm sufferers. The first three domains had been analyzed in a multivariate regression mannequin together with sociodemographic traits and previous scientific, curricular, and social experiences with AsAm. Explicit bias questions had been reported descriptively.
There had been 688 respondents. Asian race, AsAm-prevalent hometown, AsAm-related extracurricular actions, Asian language information, and having taken a inhabitants well being course predicted elevated AsAm information. Social interactions with AsAm elevated consolation with AsAm sufferers. Increasing 12 months in medical college, extra frequent publicity to AsAm sufferers on rotations, and prior journey to an Asian nation had been predictors of elevated CC towards AsAm.
Importantly, having accomplished a CC course was a big predictor in all domains. In phrases of specific bias, college students felt that AsAm sufferers had been extra compliant than Caucasian sufferers. Students additionally believed that Caucasian sufferers had been usually extra prone to obtain self-perceived “most popular” versus “acceptable” care, however that in their very own scientific experiences neither group acquired most popular care.
Experience with and publicity to AsAm previous to and through medical college and CC programs might improve medical pupil information, consolation, and CC with AsAm sufferers. Standardized and longitudinal CC coaching, elevated simulations with AsAm sufferers, numerous pupil recruitment, and assist for college kids to have interaction in AsAm-related actions and work together with AsAm might enhance CC of future physicians in the direction of AsAm sufferers and presumably different minority populations.
Personality traits are related to cognitive empathy in medical college students however not with its evolution and interventions to enhance it
Cognitive empathy would possibly lower throughout medical college. Factors related to its evolution stay poorly understood, in addition to whether or not such components might average the impact of an intervention to protect cognitive empathy. The intention was to discover the associations between character traits and each cognitive empathy at baseline and its adjustments at follow-up. The attainable impact of an intervention depended upon character traits was additionally examined.
The cohort consisted of fourth 12 months medical college students and the associations between character traits, utilizing the Short Big Five Inventory, and cognitive empathy adjustments at 3-month, utilizing the Jefferson Scale of Empathy-Student model (JSE-S), had been examined. A randomization in two teams (Balint teams versus no intervention) allowed analyzing whether or not the impact of the intervention depended upon character traits.
 [Sar1] Angiotensin II Peptide |
|
20-abx266586 |
Abbexa |
-
EUR 523.00
-
EUR 286.00
-
EUR 370.00
|
|
- Shipped within 5-10 working days.
|
 Peptide) Angiotensin II (AngII) Peptide |
|
20-abx652274 |
Abbexa |
-
EUR 523.00
-
EUR 244.00
-
EUR 1497.00
-
EUR 606.00
-
EUR 384.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
- Shipped within 5-7 working days.
|
 Peptide (OVA)) Angiotensin II (Ang II) Peptide (OVA) |
|
20-abx651045 |
Abbexa |
-
EUR 272.00
-
EUR 189.00
-
EUR 606.00
-
EUR 300.00
-
EUR 230.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
- Shipped within 5-7 working days.
|
 Peptide) Angiotensin II (4-8) Peptide |
|
20-abx265182 |
Abbexa |
-
EUR 328.00
-
EUR 495.00
-
EUR 272.00
|
|
- Shipped within 5-10 working days.
|
 Peptide) Angiotensin II (3-8) Peptide |
|
20-abx265183 |
Abbexa |
-
EUR 328.00
-
EUR 495.00
-
EUR 272.00
|
|
- Shipped within 5-10 working days.
|
 Peptide) Angiotensin II (1-4) Peptide |
|
20-abx265185 |
Abbexa |
-
EUR 523.00
-
EUR 286.00
-
EUR 370.00
|
|
- Shipped within 5-10 working days.
|
 [Asn1,Val5]-Angiotensin II Peptide |
|
20-abx266003 |
Abbexa |
-
EUR 384.00
-
EUR 592.00
-
EUR 300.00
|
|
- Shipped within 5-10 working days.
|
 [Sar1,Gly8]-Angiotensin II Peptide |
|
20-abx266581 |
Abbexa |
-
EUR 523.00
-
EUR 286.00
-
EUR 370.00
|
|
- Shipped within 5-10 working days.
|
 [Sar1,Ala8]-Angiotensin II Peptide |
|
20-abx266583 |
Abbexa |
-
EUR 523.00
-
EUR 286.00
-
EUR 370.00
|
|
- Shipped within 5-10 working days.
|
 [Sar1,Ile4,8]-Angiotensin II Peptide |
|
20-abx266584 |
Abbexa |
-
EUR 523.00
-
EUR 286.00
-
EUR 370.00
|
|
- Shipped within 5-10 working days.
|
 [Sar1,Thr8]-Angiotensin II Peptide |
|
20-abx266585 |
Abbexa |
-
EUR 523.00
-
EUR 286.00
-
EUR 370.00
|
|
- Shipped within 5-10 working days.
|
 Angiotensin II [Sar1 Ile8] Peptide |
|
20-abx266588 |
Abbexa |
-
EUR 718.00
-
EUR 328.00
-
EUR 467.00
|
|
- Shipped within 5-10 working days.
|
 Positive control tissue section for each antibody; Based on availability INQUIRE |
|
Control-Slides |
Innovex |
Set of 5 |
EUR 176 |
 Peptide) Angiotensin I / II (5-8) Peptide |
|
20-abx265760 |
Abbexa |
-
EUR 328.00
-
EUR 495.00
-
EUR 272.00
|
|
- Shipped within 5-10 working days.
|
 Peptide) Angiotensin I / II (3-7) Peptide |
|
20-abx265779 |
Abbexa |
-
EUR 328.00
-
EUR 495.00
-
EUR 272.00
|
|
- Shipped within 5-10 working days.
|
 Peptide) Angiotensin I / II (1-6) Peptide |
|
20-abx265799 |
Abbexa |
-
EUR 328.00
-
EUR 495.00
-
EUR 272.00
|
|
- Shipped within 5-10 working days.
|
 [Sar1,Val5,Ala8]-Angiotensin II Peptide |
|
20-abx266582 |
Abbexa |
-
EUR 523.00
-
EUR 286.00
-
EUR 370.00
|
|
- Shipped within 5-10 working days.
|
 Angiotensin II |
|
A1042-10 |
ApexBio |
10 mg |
EUR 108 |
|
Description: Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe | His-Leu) is an octapeptide that is converted from Angiotensin I (AI) through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE), primarily through ACE within the lung. |
Angiotensin II |
|
A1042-25 |
ApexBio |
25 mg |
EUR 131 |
|
Description: Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe | His-Leu) is an octapeptide that is converted from Angiotensin I (AI) through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE), primarily through ACE within the lung. |
Angiotensin II |
|
A1042-250 |
ApexBio |
250 mg |
EUR 630 |
|
Description: Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe | His-Leu) is an octapeptide that is converted from Angiotensin I (AI) through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE), primarily through ACE within the lung. |
Angiotensin II |
|
A1042-5 |
ApexBio |
5 mg |
EUR 84 |
|
Description: Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe | His-Leu) is an octapeptide that is converted from Angiotensin I (AI) through removal of two C-terminal residues by the enzyme angiotensin-converting enzyme (ACE), primarily through ACE within the lung. |
Angiotensin II |
|
H-7714.0005 |
Bachem |
5.0mg |
EUR 60 |
|
Description: Sum Formula: C50H71N13O12; CAS# [4474-91-3] net |
Angiotensin II |
|
H-1705.0025 |
Bachem |
25.0mg |
EUR 176 |
|
Description: Sum Formula: C50H71N13O12; CAS# [4474-91-3] net |
Angiotensin II |
|
H-1705.0100 |
Bachem |
100.0mg |
EUR 466 |
|
Description: Sum Formula: C50H71N13O12; CAS# [4474-91-3] net |
 Angiotensin II Type 1 Receptor Blocking Peptide |
|
DF7592-BP |
Affbiotech |
1mg |
EUR 195 |
 (Biotin) Peptide) Angiotensin I / II (1-7) (Biotin) Peptide |
|
20-abx266007 |
Abbexa |
-
EUR 384.00
-
EUR 592.00
-
EUR 300.00
|
|
- Shipped within 5-10 working days.
|
 Peptide) AT1A, Angiotensin II receptor, (225 237) Peptide |
|
20-abx266391 |
Abbexa |
-
EUR 523.00
-
EUR 871.00
-
EUR 384.00
|
|
- Shipped within 5-10 working days.
|
 Control/blocking peptide # 1) Human Deoxyribonuclease II (Dnase II) Control/blocking peptide # 1 |
|
DNASE21-P |
Alpha Diagnostics |
100 ug |
EUR 164 |
 Control/blocking peptide # 2) Mouse Deoxyribonuclease II (Dnase II) Control/blocking peptide # 2 |
|
DNASE22-P |
Alpha Diagnostics |
100 ug |
EUR 164 |
 Human Interferon Type II Signaling Primer Library |
|
HIFN-II |
Real Time Primers |
1 set |
EUR 548 |
 Angiotensin II protein |
|
30R-2769 |
Fitzgerald |
5 mg |
EUR 247 |
|
Description: Purified native Human Angiotensin II protein |
 Angiotensin II antibody |
|
70-1089 |
Fitzgerald |
100 ug |
EUR 727 |
|
Description: Rabbit anti-human Angiotensin II antibody |
 Angiotensin II Antipeptide |
|
5-00686 |
CHI Scientific |
4 x 5mg |
Ask for price |
Angiotensin II Antipeptide |
|
20-abx265974 |
Abbexa |
-
EUR 384.00
-
EUR 592.00
-
EUR 300.00
|
|
- Shipped within 5-10 working days.
|
Angiotensin II Antipeptide |
|
H-8160.0005 |
Bachem |
5.0mg |
EUR 273 |
|
Description: Sum Formula: C42H62N10O12; CAS# [121379-63-3] |
Angiotensin II Antipeptide |
|
H-8160.0025 |
Bachem |
25.0mg |
EUR 998 |
|
Description: Sum Formula: C42H62N10O12; CAS# [121379-63-3] |
-Angiotensin II) (Sar1)-Angiotensin II |
|
H-1740.0025 |
Bachem |
25.0mg |
EUR 273 |
|
Description: Sum Formula: C49H71N13O10; CAS# [51833-69-3] |
(Sar1)-Angiotensin II |
|
H-1740.0100 |
Bachem |
100.0mg |
EUR 756 |
|
Description: Sum Formula: C49H71N13O10; CAS# [51833-69-3] |
-Angiotensin II) (Val5)-Angiotensin II |
|
H-1750.0025 |
Bachem |
25.0mg |
EUR 273 |
|
Description: Sum Formula: C49H69N13O12; CAS# [58-49-1] |
(Val5)-Angiotensin II |
|
H-1750.0100 |
Bachem |
100.0mg |
EUR 756 |
|
Description: Sum Formula: C49H69N13O12; CAS# [58-49-1] |
 Antibody) Angiotensin II (Ang II) Antibody |
|
abx021123-02mg |
Abbexa |
0.2 mg |
EUR 1135 |
- Shipped within 5-10 working days.
|
Angiotensin II (Ang II) Antibody |
|
20-abx101258 |
Abbexa |
-
EUR 300.00
-
EUR 133.00
-
EUR 759.00
-
EUR 398.00
-
EUR 258.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
- Shipped within 5-15 working days.
|
Angiotensin II (Ang II) Antibody |
|
20-abx130645 |
Abbexa |
-
EUR 300.00
-
EUR 133.00
-
EUR 759.00
-
EUR 398.00
-
EUR 258.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
- Shipped within 5-7 working days.
|
Angiotensin II (Ang II) Antibody |
|
20-abx131719 |
Abbexa |
-
EUR 314.00
-
EUR 759.00
-
EUR 398.00
-
EUR 154.00
-
EUR 244.00
|
-
100 ug
-
1 mg
-
200 ug
-
20 ug
-
50 ug
|
- Shipped within 5-7 working days.
|
 Angiotensin Peptide |
|
20-abx265534 |
Abbexa |
-
EUR 356.00
-
EUR 537.00
-
EUR 286.00
|
|
- Shipped within 5-10 working days.
|
 amide Peptide) [Sar1]-Angiotensin I / II (1-7) amide Peptide |
|
20-abx266580 |
Abbexa |
-
EUR 523.00
-
EUR 286.00
-
EUR 370.00
|
|
- Shipped within 5-10 working days.
|
 Control/blocking peptide) Mouse Hexokinase 2 (HXK-II) Control/blocking peptide |
|
HXK23-P |
Alpha Diagnostics |
100 ug |
EUR 164 |
 ELISA Kit) Angiotensin II (Ang II) ELISA Kit |
|
abx511338-96tests |
Abbexa |
96 tests |
EUR 668 |
- Shipped within 5-12 working days.
|
 control peptide # 1) Mouse Angiotensin converting enzyme 1 (ACE-1) control peptide # 1 |
|
ACE11-P |
Alpha Diagnostics |
100 ug |
EUR 164 |
 control peptide # 2) Human Angiotensin converting enzyme 1 (ACE-1) control peptide # 2 |
|
ACE12-P |
Alpha Diagnostics |
100 ug |
EUR 164 |
 control peptide # 1) Mouse Angiotensin converting enzyme 2 (ACE-2) control peptide # 1 |
|
ACE21-P |
Alpha Diagnostics |
100 ug |
EUR 164 |
 control peptide # 2) Human Angiotensin converting enzyme 2 (ACE-2) control peptide # 2 |
|
ACE22-P |
Alpha Diagnostics |
100 ug |
EUR 164 |
 Anti-Angiotensin II Antibody |
|
A1588-100 |
Biovision |
|
EUR 338 |
Anti-Angiotensin II Antibody |
|
A1588-30T |
Biovision |
|
EUR 146 |
 [Asn1, Val5]-Angiotensin II |
|
5-00053 |
CHI Scientific |
4 x 5mg |
Ask for price |
 [Sar1, Ala8]-Angiotensin II |
|
5-00294 |
CHI Scientific |
24 x 5mg |
Ask for price |
 [Sar1, Gly8]-Angiotensin II |
|
5-00295 |
CHI Scientific |
24 x 5mg |
Ask for price |
 [Sar1, Thr8]-Angiotensin II |
|
5-00297 |
CHI Scientific |
24 x 5mg |
Ask for price |
 [Val5] Angiotensin II, human |
|
5-00373 |
CHI Scientific |
4 x 5mg |
Ask for price |
 Angiotensin II [Sar1 Ile8] |
|
5-00691 |
CHI Scientific |
24 x 5mg |
Ask for price |
 Antibody) Angiotensin II (AngII) Antibody |
|
20-abx175396 |
Abbexa |
-
EUR 411.00
-
EUR 133.00
-
EUR 1135.00
-
EUR 551.00
-
EUR 314.00
|
-
100 ug
-
10 ug
-
1 mg
-
200 ug
-
50 ug
|
- Shipped within 5-7 working days.
|
-Angiotensin II) (Asn1,Val5)-Angiotensin II |
|
H-6010.0025 |
Bachem |
25.0mg |
EUR 321 |
|
Description: Sum Formula: C49H70N14O11; CAS# [53-73-6] |
(Asn1,Val5)-Angiotensin II |
|
H-6010.0100 |
Bachem |
100.0mg |
EUR 902 |
|
Description: Sum Formula: C49H70N14O11; CAS# [53-73-6] |
 Angiotensin II Receptor Ligand |
|
H-9395.0001 |
Bachem |
1.0mg |
EUR 176 |
|
Description: Sum Formula: C52H69N13O11; CAS# [127060-75-7] |
Angiotensin II Receptor Ligand |
|
H-9395.0005 |
Bachem |
5.0mg |
EUR 611 |
|
Description: Sum Formula: C52H69N13O11; CAS# [127060-75-7] |
-Angiotensin II) (Sar1,Gly8)-Angiotensin II |
|
H-1725.0025 |
Bachem |
25.0mg |
EUR 273 |
|
Description: Sum Formula: C42H65N13O10; CAS# [51887-62-8] |
(Sar1,Gly8)-Angiotensin II |
|
H-1725.0100 |
Bachem |
100.0mg |
EUR 756 |
|
Description: Sum Formula: C42H65N13O10; CAS# [51887-62-8] |
-Angiotensin II) (Sar1,Ile8)-Angiotensin II |
|
H-1730.0025 |
Bachem |
25.0mg |
EUR 273 |
|
Description: Sum Formula: C46H73N13O10; CAS# [37827-06-8] |
(Sar1,Ile8)-Angiotensin II |
|
H-1730.0100 |
Bachem |
100.0mg |
EUR 756 |
|
Description: Sum Formula: C46H73N13O10; CAS# [37827-06-8] |
-Angiotensin II) (Sar1,Thr8)-Angiotensin II |
|
H-1745.0025 |
Bachem |
25.0mg |
EUR 273 |
|
Description: Sum Formula: C44H69N13O11; CAS# [53632-49-8] |
(Sar1,Thr8)-Angiotensin II |
|
H-1745.0100 |
Bachem |
100.0mg |
EUR 756 |
|
Description: Sum Formula: C44H69N13O11; CAS# [53632-49-8] |
) Synthetic Angiotensin II (AngII) |
|
4-SPA005Mi01 |
Cloud-Clone |
-
EUR 350.88
-
EUR 197.00
-
EUR 1040.80
-
EUR 413.60
-
EUR 727.20
-
EUR 298.00
-
EUR 2452.00
|
-
100 ug
-
10ug
-
1 mg
-
200 ug
-
500 ug
-
50ug
-
5 mg
|
- Uniprot ID: Inquire
- Buffer composition: PBS, pH 7.4.
- Form: Freeze-dried powder
- Predicted Molecular Mass (KD): 1046.2Da
- Isoelectric Point: 6.7
|
|
Description: Recombinant Human, Mouse, Rat Angiotensin II expressed in: E.coli |
 Angiotensin I Peptide |
|
20-abx265095 |
Abbexa |
-
EUR 439.00
-
EUR 495.00
-
EUR 718.00
-
EUR 1247.00
-
EUR 328.00
|
-
10 mg
-
20 mg
-
25 mg
-
50 mg
-
5 mg
|
- Shipped within 5-10 working days.
|
 Angiotensin III Peptide |
|
20-abx265119 |
Abbexa |
-
EUR 356.00
-
EUR 537.00
-
EUR 286.00
|
|
- Shipped within 5-10 working days.
|
 Angiotensin A Peptide |
|
20-abx266011 |
Abbexa |
-
EUR 384.00
-
EUR 592.00
-
EUR 300.00
|
|
- Shipped within 5-10 working days.
|
 Mouse NOS-II/i-NOS Control/blocking peptide # 1 |
|
iNOS-P |
Alpha Diagnostics |
100 ug |
EUR 164 |
 Mouse i-NOS/NOS-II Control/blocking peptide # 2 |
|
iNOS22-P |
Alpha Diagnostics |
100 ug |
EUR 164 |
 Control/blocking peptide) human Topoisomerase II alpha (TOP2 alpha) Control/blocking peptide |
|
TOP2A11-P |
Alpha Diagnostics |
100 ug |
EUR 164 |
The cohort included 311 members from October 2015 to December 2016 at Paris Diderot and Paris Descartes University. At follow-up, there was a JSE-S whole rating improve of 1.22(SD:9.10) in the intervention group, in comparison with a lower of 1.64(SD:10.74) in the different group. Baseline JSE-S was positively related to Extraversion and Conscientiousness and negatively with Neuroticism. In distinction, we discovered no associations between baseline character traits and JSE-S change. There had been no interactions between character traits and randomization group.
